Scarica l'app Stockscreener
2.8999
19.83%
0.4799
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRBU Giù?
Forum
Previsione
Precedente Chiudi:
$2.42
Aprire:
$3.4
Volume 24 ore:
56.99M
Relative Volume:
31.26
Capitalizzazione di mercato:
$266.80M
Reddito:
$34.48M
Utile/perdita netta:
$-102.07M
Rapporto P/E:
-1.9862
EPS:
-1.46
Flusso di cassa netto:
$-104.90M
1 W Prestazione:
+18.36%
1M Prestazione:
+27.75%
6M Prestazione:
+229.53%
1 anno Prestazione:
+31.22%
Intervallo 1D:
$2.78
$3.535
Intervallo di 1 settimana:
$2.275
$3.535
Portata 52W:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Nome
Caribou Biosciences Inc
Settore
Industria
Telefono
510-982-6030
Indirizzo
2929 7TH STREET, SUITE 105, BERKELEY
Confronta CRBU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.865 | 225.36M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.67 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.59 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.00 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.91 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.01 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Iniziato | Evercore ISI | Outperform |
| 2023-07-11 | Iniziato | Truist | Buy |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-17 | Iniziato | BofA Securities | Buy |
| 2021-08-17 | Iniziato | Citigroup | Neutral |
| 2021-08-17 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Caribou Biosciences Inc Borsa (CRBU) Ultime notizie
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - MSN
Caribou Biosciences expects cash and marketable securities as of Sept 30 to be $159.2 million - MarketScreener
Caribou Biosciences Reports Positive ANTLER Phase 1 Results - TipRanks
Caribou Biosciences announces results from CaMMouflage Phase 1 trial - TipRanks
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - The Manila Times
Caribou Biosciences stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com Canada
Caribou Biosciences Soars Over 120%What's Driving The Rally? - Nasdaq
Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study - statnews.com
Caribou (NASDAQ: CRBU): 51% 12-mo PFS with vispa-cel, on par with autologous CAR-T - Stock Titan
Why Caribou Biosciences Inc. stock remains on buy listsJuly 2025 PreEarnings & Fast Entry High Yield Tips - newser.com
Using Bollinger Bands to evaluate Caribou Biosciences Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
What machine learning models say about Caribou Biosciences Inc.Weekly Profit Recap & Pattern Based Trade Signal System - newser.com
Published on: 2025-11-03 00:52:40 - newser.com
Is it time to cut losses on Caribou Biosciences Inc.Risk Management & Free Expert Verified Stock Movement Alerts - newser.com
Caribou Biosciences to Host Webcast Reporting New Clinical Data for Anti-CD19 and Anti-BCMA CAR-T Cell Therapies - Quiver Quantitative
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - The Manila Times
Caribou Bio (NASDAQ: CRBU) to host Nov. 3 webcast on first CB-011 data, vispa-cel update - Stock Titan
Ranking Caribou Biosciences Inc. among high performing stocks via tools2025 Geopolitical Influence & Daily Stock Trend Watchlist - newser.com
Risk adjusted return profile for Caribou Biosciences Inc. analyzedForecast Cut & Weekly Consistent Profit Watchlists - newser.com
Statistical indicators supporting Caribou Biosciences Inc.’s strengthCPI Data & Reliable Breakout Forecasts - newser.com
Will Caribou Biosciences Inc. stock go up soonGlobal Markets & Short-Term High Return Ideas - newser.com
Is Caribou Biosciences Inc. stock a contrarian buyEarnings Beat & High Accuracy Buy Signal Tips - newser.com
Caribou Biosciences Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Intraday pattern recognizer results for Caribou Biosciences Inc.2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Caribou Biosciences Advances CRISPR-Edited CAR-T Therapy in Lymphoma Study - TipRanks
Caribou Biosciences’ Long-Term Study: A Key Update for Investors - MSN
Caribou Biosciences (CRBU) to Release Quarterly Earnings on Wednesday - MarketBeat
Caribou Biosciences Expands Genetic Innovation In Biotech - Kalkine Media
Can swing trading help recover from Caribou Biosciences Inc. lossesPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Caribou Biosciences’ CRISPR-Edited CAR-T Therapy: A Promising Step in Multiple Myeloma Treatment - TipRanks
Caribou Biosciences Inc Azioni (CRBU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):